BioMimetix JV

Focus: BioMimetix JV is a Colorado-based biotech focused on redox active metalloporphyrin therapeutics across oncology, immunology, and dermatology. Founded in 2013, the company operates as a pre-revenue biotech with an active pipeline spanning multiple cancer and inflammatory skin indications.

Oncology Immunology Dermatology

Profile data last refreshed 5h ago · AI intelligence enriched 2w ago

Open Jobs

About BioMimetix JV

AI assessmentNot Hiring

No open roles listed right now. Follow BioMimetix JV to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

11 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

BMX-001

Ovarian Neoplasms

Phase 1/2

Clinical Trials (1)

NCT06620029BMX-001 + Paclitaxel in Adult Patients With Advanced, Recurrent, Metastatic Ovarian or Endometrial Cancer

Phase 1/2

Help build intelligence for BioMimetix JV

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Portfolio breadth across oncology (4 BMX-001 cancer programs) and dermatology (4 BMX-010 skin programs) offers exposure to multiple therapeutic modalities and commercial paths
Early-stage pipeline (Phase 1/2 and Phase 2) provides opportunity to influence compound progression and clinical strategy from clinical proof-of-concept stages
Unique chemistry platform (redox active metalloporphyrins) differentiates from competitors and positions for potential first-mover advantage if efficacy validated

Watch Out For

Zero active job openings and limited company size data suggest minimal hiring or potential financial constraints limiting growth opportunities
No published data on funding, revenue, cash position, or financial health creates uncertainty about runway and long-term viability
Early-stage programs (no Phase 3 candidates) means significant clinical and regulatory risk; 5+ year minimum before any potential approval

Generated by Claude from BioMimetix JV's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

BMX-001

Head and Neck Cancer

Phase 1/2

Clinical Trials (1)

NCT02990468A Trial of Concurrent Radiation Therapy, Cisplatin, and BMX-001 in Locally Advanced Head and Neck Cancer

Phase 1/2

BMX-001

Anal Cancer, Squamous Cell Carcinoma

Phase 1/2

Clinical Trials (1)

NCT03386500Safety Study of BMX-001 (Radio-protector) in Patients With Newly Diagnosed Anal Cancer

Phase 1/2